High TMB in EGFR‐mutant lung cancers was linked to a significantly shorter overall survival in patients treated with EGFR‐TKIs.18 This finding stands in contrast to what is observed for TMB and treatment with immune checkpoint inhibitors. This evidence concerns the gene EGFR and lung cancer.